| Literature DB >> 2835468 |
F S Watson1, J B O'Connell, I J Amber, D G Renlund, D Classen, J M Johnston, C B Smith, M R Bristow.
Abstract
Cytomegalovirus (CMV) infection is a frequent cause of serious illness in heart transplant patients and may cause life-threatening pneumonia, with a reported mortality of greater than 50%. We investigated the clinical efficacy of a new antiviral agent, 9(1,3-dihydroxy-2-proproxymethyl)-guanine (DHPG) in the treatment of CMV pneumonia in heart transplant patients. Four of these patients with biopsy-proved CMV pneumonia were treated with DHPG, with resolution of pneumonia and no relapse at a mean follow-up period of 21 weeks. DHPG may be useful in the treatment of CMV pneumonia in heart transplant patients.Entities:
Mesh：
Substances：
Year: 1988 PMID： 2835468
Source DB: PubMed Journal: J Heart Transplant ISSN： 0887-2570